Urologists

The 4Kscore's 64.6% biopsy reduction rate in the 35-urologist real-world study represents a genuine capacity amplifier in a specialty where 62% of counties have no urologist at all — fewer unnecessary procedures means more clinic time for patients who need care. But the biopsy decision is never purely algorithmic: a 4Kscore of 12% in a healthy 55-year-old with a PI-RADS 4 MRI lesion has different clinical weight than the same score in a 75-year-old with significant comorbidities — you integrate the number into a complete clinical picture. On the pathology side, Paige Prostate Suite's AI-graded Gleason report (70% reduction in diagnostic errors vs. unaided pathologist review) gives you structured, reproducible tumor burden data across all 12+ cores. Review the core-by-core summary before the MDT staging conference: the distinction between Grade Group 2 with <10% tumor involvement in 2/14 cores (active surveillance candidate per PRIAS/PIVOT criteria) vs. Grade Group 2 with 30% involvement in 8/14 cores (more likely to trigger definitive treatment) is a clinical interpretation that AI provides the inputs for but that the urologist synthesizes into a management plan. OpenEvidence provides instant NCCN/AUA risk group criteria and active surveillance eligibility lookup.

Unfold AI changed treatment recommendations in 28% of cases in its pivotal clinical study — frequently shifting toward more localized, organ-preserving treatment when the AI-predicted cancer extent was more confined than radiologist or clinical estimation suggested. The 90% negative margin prediction rate vs. 0% with conventional methods is the strongest argument for integrating AI-guided margin planning into focal therapy workflows. The urologist's irreplaceable contribution is the shared decision-making conversation that precedes any focal therapy booking: discussing the 20-30% recurrence risk unique to focal treatment (vs. radical prostatectomy's 10-15%), the patient's specific priorities around erectile function, urinary control, and cancer certainty, and the data gaps that arise when AI cancer maps are built from systematic + targeted biopsy data that may have sampling error. Unfold AI is an FDA-cleared decision-support tool; the clinical judgment about whether focal therapy is the right approach for a given patient — integrating age, life expectancy, comorbidities, and patient values — remains entirely physician-led.

AI-tracked MRI-US fusion biopsy is now the AUA guideline-recommended approach for biopsy-naïve patients with PI-RADS ≥3 lesions on mpMRI (AUA 2026 guideline update). KOELIS Trinity's OBT motion compensation achieves targeting precision that is not achievable with cognitive registration or older electromagnetic-tracked systems — the 2.5mm accuracy matters when targeting a 6mm PI-RADS 4 lesion in the posterior horn. Promap Contour's AI-automated MRI segmentation removes the manual contouring step that previously required a radiologist consultation in the pre-procedure workflow; the urologist now receives a ready-to-load target package. The biopsy remains a manual, needle-passing procedure — you control the needle, select core sites to supplement systematic sampling, and make the intraoperative call on adequacy. The 4Kscore pre-biopsy probability anchors your indication decision: for a PSA-elevated patient with 4Kscore <7.5% and negative mpMRI, the evidence now supports deferring biopsy — avoiding the 1-2% serious infection risk (sepsis) and quality-of-life impact of an unnecessary procedure. Know the false-negative profile of MRI (10-15% of Grade Group 2+ cancers are MRI-invisible) to ensure systematic sampling always accompanies targeted sampling.